Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
Daiichi Sankyo rolled out its oncolytic virus Delytact (G47∆; teserpaturev) in Japan on November 1. It will initially supply the therapy to medical institutions where its clinical trials were conducted but hopes to set up a stable supply system as…
To read the full story
Related Article
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
BUSINESS
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Otsuka Files Esperion’s Cholesterol Fighter in Japan
November 27, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
November 26, 2024
- Kyowa Kirin Recalls Regpara after Nitrosamine Detection
November 25, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…